Fundamental Data for UTHR

UTD THERAP(NSDQ:UTHR)

UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.

# Employees: 360

Address: 1110 Spring Street,Silver Spring,MD,USA

Phone: 301 608-9292

Fax: 301 608 9291

Website: www.unither.com

Email: ir@unither.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Martine A. Rothblatt PhD (J)

Chmn.; C.E.O.; Dir. (Roger Jeffs Ph.D.)

Presi.; C.O.O.; Dir. (John M. Ferrari)

C.F.O.; Treas. (Paul A. Mahon J.D.)

Exec. V.P.; Strategic Planning; Gen. Consl.; Corp. (Christopher Causey,Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/16/2010

Mean EPS (Next Qtr): $0.29

Mean EPS (Year): $0.79

Mean Estimate(Long Term): $46.00

P/E Ratio(Based on EPS estimate): 57.180

Number of Estimates: 13

Shares Performance

Period	UTHR	Compare to S&P
YTD	43.60 %	18.84 %
4 Weeks	5.47 %	4.33 %
12 Weeks	-2.50 %	-8.08 %

Shares Information

Analyst Coverage: Y

Avg Volume: 616165

Shares Outstanding: 53M

Market Cap: $2.39B

52 Week High: $50.29

52 Week Low: $24.50

P/E Ratio: 53.780

PEG Ratio: 1.240

Split: On 9/23/2009 UTHR split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 566.67 %

EPS Growth in Last Year: -16.00 %

Sales Growth in Last Quarter: 15.76 %

Sales Growth in Last Quarter: 29.56 %

Financials

Qtr Book Value: $3.73

Cash Flow/Share: $23.97

Change in Payout Ratio: 0.000

Price/Sales: 7.090